In chronic heart failure (HF) from systolic cardiac dysfunction, the degree of exercise intolerance is not directly related to the degree of cardiac weakness. Somewhat surprisingly symptoms that typify HF, including shortness of breath and fatigue, are often directly related to the abnormalities of the skeletal musculature in HF. Our understanding of the features of skeletal myopathy is evolving as therapy for HF is changing and improving. Understanding the skeletal myopathy of HF is important for 2 reasons: (1) therapies, including heart transplantation, only directed at improving cardiac function, will not immediately and may never improve exercise capacity in HF, and (2) with greater understanding of the mechanisms underlying the skeletal myopathy of HF, specific therapies targeting these abnormalities can be developed.

I will review the features of the skeletal myopathy of HF, as currently understood, based on state-of-the-art research in humans and animal models. I will then examine the mechanisms underlying the skeletal myopathy, which appears not to be unique to HF but are shared by other chronic diseases such as chronic obstructive pulmonary disease (COPD) and chronic renal disease. Specifically, the role of “coordinated adaptation,” an energy-conserving strategy to maximize efficiency in a damaged system, will be examined in the development of the skeletal myopathy in all of these chronic diseases. Further, I will present evidence supporting the concept that sympathetic nerve activation (SNA) initiates and maintains this systemic, coordinated adaptation. Finally, the impact of current and future pharmacological and nonpharmacological therapies will be related to the above pathophysiology of the skeletal myopathy of HF.

What Are the Salient Features of the “Skeletal Myopathy” of HF, and Do These Features Correlate With Diminished Exercise Capacity?

There are several features of the skeletal myopathy that have been described and confirmed by many different investigative groups. Patients with chronic HF on stable medical therapy have decreased muscle bulk compared with healthy humans. The cross-sectional area of lower extremity musculature in HF is significantly smaller than that in healthy humans, and importantly, is correlated with decreased peak oxygen consumption. Morphometric analyses of muscle biopsies from patients with chronic HF have revealed a shift in fiber type, from slow-twitch, oxidative type I fibers to fast-twitch, glycolytic type IIb fibers. Once again, the shift in fiber type has been correlated with diminished exercise capacity as estimated by peak oxygen consumption (Figure 1A). The methodology used to quantify capillary density in HF has not been uniform, leading to contradictory results. Mancini et al have reported that the number of capillaries per area of muscle is actually increased. However, they attributed this to muscle fiber atrophy. When capillaries are quantified per fiber, the number of capillaries is not different or is less compared with that of control subjects. Duscha et al used cell-specific antibodies to measure capillary density and found that capillary density was significantly decreased in HF patients compared with control subjects. Importantly, when quantified in this manner, capillary density was directly correlated with maximal oxygen consumption.

Muscle metabolism is abnormal during exercise in patients with HF. Using nuclear magnetic resonance spectroscopy, several groups have reported greater phosphocreatinine depletion and early and excessive acidification in the skeletal muscle of HF patients compared with control subjects, consistent with reliance on glycolytic rather than oxidative metabolism. Not surprisingly, the patients with the lowest phosphocreatinine and pH levels are the patients with the most impaired exercise ability.

Abnormalities at the mitochondrial level have been correlated with a decrease exercise capacity in patients with HF (Figure 1B). Drexler et al used electron microscopy to quantify mitochondrial density in HF patients compared with control subjects and found it to be significantly diminished. Several other investigators have reported significantly diminished activity of mitochondrial enzymes involved in oxidative metabolism. Significantly, the abnormalities in mitochondrial density and activity are strongly related to decreased peak oxygen consumption in HF patients.

In summary, the salient features of the skeletal myopathy of HF are muscle fiber atrophy and fiber type shift from oxidative to glycolytic fiber types, decreased capillary number per muscle fiber, rapid depletion of high-energy phosphates and rapid
decrease in muscle pH during exercise, and decreased mitochondrial density and oxidative enzyme content. Consistent with the hypothesis that the skeletal myopathy in HF limits exercise capacity, each of these features has been correlated with decreased exercise capacity in patients with chronic HF.

Controversy in the Role of Mitochondrial Oxidative Metabolism

Although a compelling and appealing explanation for the exercise dysfunction in HF, the story of the skeletal myopathy of HF as outlined thus far may be incomplete.

Figure 1. A, Fiber type shift correlates with decreased exercise capacity. Morphometric analyses of muscle biopsies from HF patients have revealed a shift in fiber type, from slow-twitch, oxidative type I fibers to fast-twitch, glycolytic type IIb fibers. The shift in fiber type correlates with diminished exercise capacity as estimated by peak oxygen consumption. B, Decreased mitochondrial density correlates with decreased exercise capacity. Quantified by electron microscopy, volume density of the mitochondrial in HF is significantly diminished compared with control subjects. See text for discussion. Filled squares indicate HF and open squares, control subjects. Reprinted with permission from Wolters Kluwer/Lippincott Williams & Wilkins.

Figure 2. Correlation between exercise capacity and muscle oxidative capacity. HF patients have lower exercise capacity but similar muscle oxidative capacity compared with sedentary control subjects; both exercise capacity and muscle oxidative capacity are lower in these groups compared with active control subjects. The decreased exercise capacity in HF, therefore, cannot be entirely attributed to decreased muscle oxidative capacity. Open circles indicate HF; open triangles, sedentary control subjects; and closed triangles, active control subjects. Modified from Reference 16.

Intrinsic Mitochondrial Function

Mettauer et al16 examined the intrinsic mitochondrial function in situ rather than selective enzyme activity in homogenized specimens in intact muscle biopsies from patients with chronic HF on optimal therapy and compared them with true sedentary as well as active control subjects. HF patients compared with sedentary and active control subjects had diminished exercise capacity as measured by peak oxygen consumption and ventilation threshold; selective mitochondrial enzyme activity was diminished as well. Surprisingly, however, the muscle (mitochondrial) oxidative consumption was not different in HF patients compared with the sedentary control subjects(Figure 2). Muscle mitochondrial oxidation was diminished in both of these groups compared with the active control group. The investigators point out that the mitochondrial oxygen consumption (the tricarboxylic acid cycle) is not limited by a rate limiting enzyme and that although individual enzyme activity levels are diminished in HF, they are apparently still in sufficient quantity to maintain normal mitochondrial respiration. These findings have been confirmed by other investigators.17

These investigators have reopened the question of what additional factors in the skeletal musculature, other than mitochondrial oxidative metabolism, may lead to decreased exercise capacity in chronic HF patients on optimal therapy.

Skeletal Muscle Excitation-Contraction Coupling

After depolarization of the sarcolemma, calcium is released from the intracellular calcium storage site, the sarcoplasmic reticulum(SR), through type 1 ryanodine receptors (RyR1) (Figure 3). Intracellular calcium concentration rapidly increases, binding troponin C, allowing myosin and actin cross bridges to form, leading to muscle contraction in a process called excitation-contraction (E-C) coupling. Calcium is then rapidly sequestered in an energy-requiring reaction utilizing the sarco(endo)plasmic reticulum Ca\textsuperscript{2+}-ATPase (SERCA). Abnormalities of E-C coupling have been identified in HF, although much of the work has focused on cardiac but not skeletal muscle E-C coupling.
In animal models of HF, some but not all investigators have found the skeletal muscle RyR1 to be “leaky,” that is, prone to opening at rest, allowing calcium to leak into the cytoplasm from the SR. Leaky RyR1 channels result in reduced calcium release from the SR during contraction, and slow calcium reuptake after contraction, thereby negatively impacting muscle contraction. Further, increased cytoplasmic calcium concentration may have toxic effects, including excessive energy utilization, apoptosis, myofibrillar disarray, and transcriptional changes. Importantly, in a rat model of HF, the level of RyR1 dysfunction is correlated with early fatigue in isolated muscle experiments (Figure 4). Although controversial, these data have contributed to the concept that the skeletal myopathy of HF may essentially be an example of abnormal E-C coupling.

After calcium release, calcium is rapidly sequestered via SERCA isoforms back into the SR. In animal models of HF and in studies of the explanted heart in HF patients undergoing cardiac transplantation, cardiac SERCA2a levels are often diminished compared with normal control subjects, and calcium sequestration is slowed. Whether skeletal muscle SERCA levels and activity are also diminished has not been studied. Interestingly, in the skeletal muscle of patients with COPD, another chronic disease characterized by skeletal myopathy, SERCA activity was indeed found to be reduced, and calcium uptake was found to be slower compared with control subjects. These investigators postulated that the presence of reactive oxygen species (ROS) in skeletal muscle in COPD may lead to SERCA damage and dysfunction. ROS are, of course, also present in the skeletal muscles of patients with HF.

In summary, abnormalities of calcium cycling have been identified in the heart and skeletal musculature in patients with HF and other chronic diseases. These studies support the concept that the skeletal myopathy of chronic HF is an example of abnormal E-C coupling.

**Stress and the Concept of “Coordinated Adaptation”**

It has been hypothesized that the skeletal myopathy of HF and other chronic diseases such as COPD and chronic renal failure represent a strategy to conserve energy and maintain the operation of the damaged biological system in the most efficient manner. Thus, the skeletal myopathy of chronic HF may be the predictable and logical sequelae after a primary cardiac disturbance. According to the concept of “coordinated adaptation,” the development of an abnormality in 1 step of a multistep pathway initiates a readjustment of all other steps in the pathway to achieve a new equilibrium. Coordinated adaptation has replaced the concept of a rate-limiting step in governing many biological processes, including oxygen transport, the tricarboxylic acid cycle, and photosynthesis. In a system governed by coordinated adaptation, all steps contribute similarly and in a coordinated fashion to regulation of substrate flux. In a system governed by coordinated adaptation, no excessive reserves are maintained because maintaining excessive reserves is metabolically expensive and inefficient.
Exercise necessitates adequate oxygen transport and delivery to meet the increased oxygen requirements in exercising muscle. Oxygen transport is a multistep pathway in which the cardiovascular system works alongside the pulmonary, hematologic, and metabolic systems to ensure adequate oxygen transport. According to the theory of coordinated adaptation, when an acute, primary cardiac disorder becomes chronic, such as when an acute myocardial infarction progresses to chronic systolic dysfunction, the reserves of oxygen transport capacity in the periphery are unused and superfluous. In this setting, maintaining an excessive oxidative muscle mass in a patient with a severely limited cardiac output might impose large energetic requirements to maintain a reserve capacity unlikely ever to be utilized. Thus, a system governed by coordinated adaptation ensures that the overall efficiency of the system is optimized by matching all steps at a lower functional level (Figure 5).

The chronic condition of COPD may be an additional example of coordinated adaptation, in which a skeletal myopathy, sharing many of the features of the skeletal myopathy of HF, is present. In these chronic conditions, reduced muscle mass, fiber atrophy and switch from oxidative to glycolytic fiber types, decreased oxidative enzyme content and mitochondrial density have all been described.

### How is the Downregulation of All Systems Involved in Oxygen Transport Signaled and Coordinated Throughout the Body?

All of these chronic conditions, HF, COPD, and chronic renal disease, share the common feature of a stressed system. In each case, SNA is chronically elevated, approaching a chronic flight or fight condition. Although acutely life-saving, chronic activation of the sympathetic nervous system has many deleterious consequences. In chronic HF, I hypothesize that sympathetic excitation provides an important signal to the skeletal musculature that there has been a primary cardiac injury (Figure 6). SNA may directly and indirectly, through cytokine release, then lead to the coordinated, secondary downregulation of the other steps in oxygen transport, especially downregulation of the skeletal muscle capacity.

In summary, increased SNA during acute cardiac injury becomes chronic and may be the signal to other organs and tissues to decrease oxygen transport capacity.
How Could SNA Signal This Coordinated Downregulation of the Oxygen Capacity in Skeletal Muscle, Resulting in This Skeletal Myopathy?

SNA Leads to Inadequate Blood Flow
Increased SNA is a major contributor to the peripheral vasoconstriction in HF. Resting and reflex increases in SNA are the major mechanisms limiting increased limb blood flow during exercise in HF. In addition to restricting the quantity of limb blood flow during exercise, increased SNA may also alter the blood flow distribution in patients with HF. During exercise in healthy humans, vasoconstrictor SNA is offset by the generation of metabolic by products that produce vasodilation. However, when SNA is exaggerated, as is the case in HF, the balance between vasoconstriction and vasodilation shifts toward vasoconstriction. Inadequate perfusion may lead to areas of underperfusion and ischemia, followed by release of ROS, triggering muscle inflammation, and contributing to the skeletal myopathy of HF.

SNA Leads to Inflammation
Ample evidence supports the concept that HF from systolic dysfunction leads to a systemic inflammatory response. This inflammation involves the skeletal musculature, and contributes importantly to the skeletal myopathy of heart failure. HF patients have increased circulating tumor necrosis factor (TNF-α), associated with protein loss and cachexia. TNF-α and interleukin-6 have been linked to increased skeletal muscle catabolism, and apoptosis. In experimental models, increased levels of TNF-α are correlated with the degree of apoptosis in skeletal muscle in HF. Interleukin-6 levels are inversely correlated to muscle fiber thickness in heart failure patients. Adams et al found that interleukin-1β and iNOS levels were significantly increased in muscle biopsies from HF patients compared with control subjects. Nuclear factor-κB is an important transcription factor for proinflammatory gene expression. IL-1β mediates iNOS induction, which could be inhibited in cultures of skeletal muscle by inhibition of Nuclear factor-κB. Excessive iNOS levels may interfere with mitochondrial oxidative enzyme activity, thereby reducing oxygen uptake and exercise capacity.

Although the release of TNF-α from the heart and bacterial translocation across the bowel wall both may trigger inflammation, sympathetic hyperactivity is the major activator of inflammation in HF. Sympathetic hyperactivity leads to local areas of underperfusion in skeletal muscle leading to generation of ROS, a well-known stimulus for TNF-α. Chronic HF patients with cachexia have been found to have markedly increased catecholamine and TNF-α levels, compared with noncachectic patients, in whom levels were near normal. Sympathetic activation typifies other chronic diseases, such as COPD and chronic renal failure, which are also characterized by systemic inflammation and skeletal myopathy.

Increased SNA Leads to Abnormal Metabolism
In addition to producing tissue hypoxia, oxidative stress, and inflammation, sympathetic nerve activation has direct effects on metabolic processes. Infusion of catecholamines into working muscles in healthy animals and humans produces an increased lactic acid output, even in the absence of hypoxia. Thus, one explanation for the premature and excessive production of lactic acid in humans with HF during exercise may be a direct metabolic effect of catecholamines in myocyte metabolism.

Increased SNA Contributes to E-C Coupling Abnormalities
Chronic sympathetic nerve activation in chronic HF leads to protein kinase A phosphorylation of the tetrameric RyR1 complexes, leading to dissociation of the calstabin molecule from the channel complex. Calstabin stabilizes the RyR1 channel in the closed state, and in its absence the RyR1 becomes leaky.

In summary, after an acute cardiac injury, such as a myocardial infarction, SNA acutely increases to maintain blood pressure and cardiac output. However, chronically elevated SNA also has detrimental effects, including vasoconstriction, tissue hypoxia, ROS generation, abnormal E-C coupling, and initiation of inflammation.

But What About Deconditioning?
Deconditioning contributes to the skeletal myopathy of HF. Deconditioning can cause several but not all of the features present in patients with HF. Increased physical activity reverses many of the features of skeletal myopathy, and even more importantly, reverses the purported instigators of the myopathy, elevated SNA and inflammation.

Deconditioning is not the sole mechanism of skeletal muscle dysfunction in HF, however. In the rat infarct model of HF, HF rats and sham-operated rats had a similar activity level in the 8 weeks after operation (left coronary ligation or sham), yet the HF rats developed skeletal myopathy. HF rats exhibited a fiber shift from oxidative to glycolytic fiber type, and a decrease in mitochondrial enzyme activity. Furthermore, mRNA for cytochrome oxidase and β-myosin heavy chains were decreased, and message for glycolytic myosin heavy chain IIx and IIb were increased. The skeletal myopathy in this rat model of HF, which resembled that in human HF, could not be explained by disuse.

There are important differences in the skeletal myopathy of disuse and that of chronic HF. In deconditioning, atrophy in both fiber muscle types I and II are present but preferentially type II. In HF, type I is predominantly atrophied. Deconditioning preferentially affects the postural muscles, sparing small muscles of the arms and the muscles of respiration. The skeletal myopathy of HF is systemic. Finally, HF is characterized by early and severe muscle fatigue that exceeds the degree of mitochondrial enzyme deficiency. In summary,
although disuse contributes to the skeletal myopathy of chronic HF, there are other important, contributing factors.

**Why Is Resting and Exercise-Related SNA Elevated in Chronic HF?**

Sympathetic activation after an acute cardiac injury is intuitive and easily understood. Initially sympathetic activation increases contractility, regulates blood flow, maintains blood pressure, and modulates glucose metabolism. However, prolonged, chronic sympathetic activation is maladaptive, leading to decreased capillary recruitment, and generation of ROS, initiation of inflammation, and the myopathic features of HF, as well as hyperphosphorylation of ryanodine receptors, leading to a E-C coupling myopathy.1–5 Persistent sympathetic activation in HF has been attributed to (1) decreased inhibitory reflexes, including blunted arterial or cardiopulmonary reflexes, (2) augmented excitatory reflexes, including heightened arterial chemoreceptor sensitivity and muscle somatic afferents, and/or (3) enhanced central nervous system influences. Below is a brief summary of the muscle somatic afferent contribution; the reader is directed to several excellent reviews.46–48

In the 1990s, Coats et al49 developed the “Muscle Hypothesis,” in which they postulated that overactivity of the somatic afferents located in skeletal muscle, maintains increased SNA both at rest and during exercise. Muscle metaboreceptors are somatic afferents located in the skeletal muscle, which are sensitive to ischemic metabolites generated during exercise. This receptor type plays a major role in increasing blood pressure and SNA (“the exercise pressor reflex”) during exercise in healthy humans. Muscle mechanoreceptors are another type of somatic afferent nerve fiber that are sensitive to stretch and also play a role, albeit minor, in mediating the exercise pressor reflex in healthy humans. Coats et al attributed the overactivity of muscle afferents to the abnormal skeletal muscle milieu of HF.

My group and others46–47 have reported that muscle metaboreceptor sensitivity is blunted and muscle mechanoreceptor sensitivity is increased in patients with HF, thereby potentially identifying this nerve fiber type as the culprit in mediating increased SNA at rest and during exercise in chronic HF. However, other investigators46,47 have reported exaggerated muscle metaboreceptor sensitivity during exercise in HF. Thus, although investigations in patients with HF have reported exaggerated sympathetic and hemodynamic responses during exercise, the relative contributions of the muscle metaboreceptors and muscle mechanoreceptors is controversial, perhaps due to heterogeneity of patient populations, and failure of current experimental techniques to isolate entirely specific nerve fiber types.

Animal models provide a more homogeneous study group, and the potential to isolate selectively and precisely the specific nerve endings of interest for study.47 In the decerebrate rat infarct model of HF, capsaicin was used to selectively activate muscle metaboreceptors of the hind limb skeletal muscle.47 Capsaicin elicited dose-related increases in blood pressure and heart rate, but these were blunted compared with non-HF control rats. In this same model, activation of the muscle mechanoreceptors by passive stretch of the hind limb, greater increases in blood pressure and heart rate were elicited in HF compared with control rats. In summary, findings in animal models of HF support the findings in humans with HF that muscle mechanoreceptors underlie the exaggerated neurovascular responses to exercise in chronic HF.

**How Do Our Current Therapies Affect the Skeletal Myopathy of HF, and How Does Our Present Understanding of the Skeletal Myopathy of HF Affect Future Therapies?**

**Pharmacological Therapies**

Interruption of the effects of angiotensin II in HF, either with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockade, results in improvements in the skeletal myopathy of HF. As noted above, in HF patients on chronic therapy with ACEI, mitochondrial oxidative function is not significantly different from that of healthy but sedentary control subjects.46 In the infant model of HF in rats, treatment with ACEI, initiated 7 days after myocardial infarction, protected mitochondrial oxidative function and mRNA transcription of mitochondrial enzymes, which were abnormal in the untreated HF rats.51 Vescovo et al52 examined muscle biopsies in humans with HF before and after 6 months of treatment with ACEI (n=8) or losartan (n=8). Slow myosin heavy chain MHC1 increased, and fast oxidative MHC2A and fast glycolytic MHC2b significantly decreased on each therapy and were associated with increased exercise capacity as estimated by increased peak oxygen capacity in each group.52 Mechanisms underlying the improvement in the skeletal myopathy with ACEI are unknown. One intriguing possibility is the inhibition of the deleterious effects of angiotensin on insulin-like growth factor-I (IGF-1). In rats, angiotensin II infusion downregulates IGF-1, leading to muscle proteolysis, specifically, actin cleavage and apoptosis.53 Thus, therapy with ACEI may potentially block this IGF-1 downregulation. Therapy specifically developed to increase local IGF-1 in HF may be a novel strategy to reverse the skeletal myopathy of HF.53

β-Adrenergic blockade has been associated with improvement in exercise capacity in humans with HF. In animal models of HF, less protein oxidation is present in animals treated with β-blockade compared with placebo, and the findings are greatest in animals treated with carvedilol, which has antioxidative properties as well.54

We have preliminary data (unpublished observations) in muscle biopsies obtained in 7 chronic HF patients who were optimized on medical therapy including ACEI and β-adrenergic blockers for at least 3 months. Many of the classic findings of this skeletal myopathy of HF, including changes in capillary density, mitochondrial enzyme activity, and myofibrillar size, were all, with rare exceptions, within normal limits. Nonetheless, exercise capacity remained depressed in this small group of heart transplant candidates, peak VO₂ 15.9 mg/kg. Analysis of E-C coupling in these HF patients is planned.

Therapies directed at the mediators of inflammation in HF have not been successful.55,56 Trials to interrupt TNF-α activity with recombinant chimeric soluble TNF receptor type
2 were halted due to lack of efficacy. Anti–TNF-α chimeric monoclonal antibody, infliximab, was halted early due to increased deaths and hospitalizations in the drug group compared with placebo. These disappointing results do not disprove the important role of TNF-α and inflammation in the progression of HF yet do challenge us to find alternate targets and directed therapies in advanced HF patients.

To restore E-C coupling in skeletal muscle in chronic HF patients, a pharmacological approach to prevent the dissociation of calstabin I from the RyR1 has been proposed. In mice with HF, rycals, small molecules that essentially fix the leak in RyR1, have been shown to improve muscle fatigue. Trials of the pharmacological agents to enhance SERCA activity, and even gene transfer of SERCA2a, have been shown to improve cardiac function; the impact of these strategies on skeletal muscle function have not been reported. Further work is necessary to determine if these approaches will improve exercise capacity in HF.

Chronic HF is associated with endocrine deficiencies that may have catabolic effects. Many HF patients are growth hormone (GH) deficient, and many men with HF may be testosterone deficient. Therapy with GH in those with low GH levels, or with testosterone in male HF patients, has each been shown to improve exercise performance in placebo-controlled trials. Unfortunately, muscle biopsies were not done, so the effect of these therapies on the skeletal myopathy remains unknown.

Finally, molecular therapies for skeletal myopathy are on the horizon. Gene therapy with SERCA2 was mentioned above. Myoblast transplantation is also being studied. Myoblasts are easily procured and grown, but thus far, clinical trials have been hampered by poor myoblast survival and migratory ability.

In summary, present therapies with β-blockade and ACEI, although beneficial to the heart, may actually have their greatest impact on reversing the skeletal myopathy of HF. Nonetheless, exercise capacity remains diminished, mandating the development of future therapies directed at abnormalities of E-C coupling, proteolysis and apoptosis.

Nonpharmacological Therapies

Cardiac Resynchronization Therapy

Cardiac resynchronization therapy has been shown to improve exercise capacity in chronic HF patients. This benefit may be attributable to improvements in ejection fraction or hemodynamics. Additionally, reduced SNA in patients treated chronically with cardiac resynchronization therapy may lead to improved skeletal muscle function. Grassi et al recorded SNA directly using the technique of microneurography and found that SNA was decreased by approximately 30% 2 months after biventricular pacemaker implantation. Unfortunately, muscle biopsies were not obtained to assess whether the decrease in SNA was accompanied by improvement in muscle inflammation and the skeletal myopathy of HF. These studies are ongoing in our laboratory.

Exercise Training

Exercise training in chronic HF improves quality of life, exercise capacity, and functional class and has been the subject of several excellent reviews (Figure 7). These improvements are associated with reversal of many of the histochemical and morphometric features of skeletal myopathy and may be seen within 2 months of initiation of an exercise program. Skeletal muscle atrophy and fiber shift can be largely reversed with exercise training. Volume density of mitochondria is improved, and oxidative capacity of the mitochondria, estimated by individual enzyme activity, is increased. Exercise training also reduces the early phosphocreatine depletion and early and excessive acidification that occurs during exercise. The marked improvement of the skeletal myopathy with exercise in HF lends support to the concept that deconditioning is one mechanism underlying this skeletal myopathy. Additional mechanisms underlying the reversal of the skeletal myopathy with exercise training include improvements in limb blood flow, decreased SNA, and reduced muscle inflammation.

Exercise training improves endothelially mediated (nitric oxide–dependent) peripheral blood flow without improving cardiac function. Exercise training may both increase availability of nitric oxide by increasing endothelial nitric oxide expression and/or increasing antioxidant enzymes that decrease oxygen free radicals that interfere with nitric oxide.

Exercise training in chronic HF patients reduces resting SNA. Coats et al reported that 8 weeks of exercise training in chronic HF patients significantly reduced whole body norepinephrine spillover and improved heart rate variability. Negrao et al reported that 4 months of exercise training significantly reduced SNA, directly measured with microneurography, in advanced HF patients randomly assigned to exercise training but not in the advanced HF patients randomized to no training or the healthy, trained control subjects. In fact, SNA in the HF group after training was no longer greater than the SNA in the trained control subjects (Figure 8). The mechanisms underlying this normalization of SNA with training in HF were not explored, but a modulation of peripheral reflexive influences on central sympathetic outflow or the reduction of excitatory influences located centrally may be involved. Studies are ongoing to investigate peripheral reflexive influences.

Exercise training has chronic antiinflammatory effects on the skeletal musculature in HF. Gielen et al studied 20 chronic HF patients: 10 randomly assigned to 6 months of
exercise training and 10 sedentary control subjects. Peak oxygen consumption was significantly improved in the trained group. Skeletal muscle TNF-α, IL-6, and IL-1-β were significantly decreased in the trained HF group but were unchanged in the sedentary group. Further, skeletal muscle iNOS was significantly reduced in trained HF patients.

In summary, exercise leads to improved peripheral blood flow, decreased sympathetic activation, and decreased skeletal muscle inflammation. Whether all of these mechanisms are linked and mechanistically intertwined remains unknown but likely.

**Persistent Questions**

Although it is generally agreed that exercise limitation in chronic systolic HF is attributable to abnormalities of the skeletal musculature, the exact nature of those abnormalities is uncertain. Previously described abnormalities of fiber shift from oxidative to glycolytic types and insufficient limb blood flow are markedly improved by pharmacological therapies, yet patients still have exercise limitations. Abnormalities in mitochondrial activity seem also to have been largely corrected by pharmacological therapy. Reduced mitochondrial oxidative capacity may have been overstated; mitochondrial oxidative capacity appears to be similar to that of sedentary control subjects when approached with newer experimental techniques. Might not the abnormalities of the E-C coupling, increased proteolysis mediated by suppression of IGF-1, or other abnormalities, such as hormone deficiencies, play a role in the pathophysiology, and thus serve as therapeutic targets? Finally, because the skeletal musculature is the limiting factor in exercise ability in patients with HF, it follows that increased activity improves this limitation. How much exercise and what type(s) of exercise of training are necessary to see a sympatholytic effect remain to be determined.

**Sources of Funding**

Dr Middlekauff is supported by NIH-RO1 HL084525 and the University of California, Los Angeles, General Clinical Research Center NIH-MO1-RR00865.

**Disclosures**

None.

**References**

Middlekauff Skeletal Myopathy of Heart Failure


Making the Case for Skeletal Myopathy as the Major Limitation of Exercise Capacity in Heart Failure
Holly R. Middlekauff

Circ Heart Fail. 2010;3:537-546
doi: 10.1161/CIRCHEARTFAILURE.109.903773
Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/3/4/537

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Heart Failure can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Heart Failure is online at:
http://circheartfailure.ahajournals.org//subscriptions/